Observational studyBMC gastroenterology2025
The prognostic significance of tumor-specific growth factor in colorectal cancer: an observation study.
Observational study in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe correlation between tumor-specific growth factor (TSGF) and the prognosis of colorectal cancer (CRC)has not been extensively studied. Research was designed to evaluate the potential of TSGF as a predictive marker for the prognosis of patients with CRC.
methodsThe serum TSGF was quantified and stratified into elevated/normal groups based on the established threshold detected using the rate method. The log-rank test was employed for survival analysis to evaluate the 3-year overall survival (OS). Prognostic independence was verified through Cox proportional hazards model. The receiver operating characteristic (ROC) curves were plotted to assess the clinical application value of TSGF.
resultsA total of 2223 patients were incorporated in our study. The survival analysis revealed that elevated TSGF levels were associated with poorer survival in CRC. The multivariate Cox analysis demonstrated TSGF as an independent prognostic factor. The signature covering TSGF with T staging, N staging, CEA, CA199 demonstrated superior predictive capability based on the Area Under the Curve (AUC) (Delong's test p = 0.025).
conclusionTSGF is an independent factor correlating with the 3-year OS of stage I-III CRC patients. Moreover, our new signature including TSGF can effectively improve the prognostic evaluation of CRC, thereby contributing to precision medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.